Biogen executive says its Alzheimer’s drug will do well in market despite competition

(Reuters) – Biogen’s Alzheimer’s drug, Leqembi, will do well in the market, whether a competitor will come or not, a company executive said at the Goldman Sachs Global Healthcare Conference on Wednesday.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)